Status:
COMPLETED
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Pneumococcal Infections
Eligibility:
All Genders
42-90 years
Phase:
PHASE3
Brief Summary
This study will evaluate the safety and tolerability and immunogenicity of V114 when administered to 2-month old infants. The primary hypotheses are: 1) V114 is non-inferior to Prevenar 13™ for the 13...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Healthy
- Has a legally acceptable representative who understands the study procedures, alternate treatments available, and risks involved with the study and voluntarily agrees to participate by giving written informed consent
- Exclusion Criteria
- History of invasive pneumococcal disease \[(IPD); positive blood culture, positive cerebrospinal fluid culture, or other sterile site\] or known history of other culture positive pneumococcal disease
- Has a known or suspected impairment of immunological function
- Has a history of congenital or acquired immunodeficiency
- Has, or his/her mother has, a documented human immunodeficiency virus (HIV) infection
- Has, or his/her mother has, a documented hepatitis B surface antigen - positive test
- Has known or history of functional or anatomic asplenia
- Has failure to thrive based on the clinical judgement of the Investigator
- Has a bleeding disorder contraindicating intramuscular vaccination
- Has a history of autoimmune disease (including but not limited to systemic lupus erythematosus, antiphospholipid syndrome, Behcet's disease, autoimmune thyroid disease, polymyositis and dermatomyositis, scleroderma, Type 1 diabetes mellitus, or other autoimmune disorders)
- Has a known neurologic or cognitive behavioral disorder, including encephalitis/myelitis, acute disseminating encephalomyelitis, pervasive development disorder, and related disorders
- Has received a dose of any pneumococcal vaccine prior to study entry
- Has received \>1 dose of monovalent hepatitis B vaccine or hepatitis B-based combination vaccine prior to study entry
- Has received a dose of any acellular pertussis- or whole cell pertussis-based combination vaccines, Haemophilus influenzae type b conjugate vaccine, poliovirus vaccine, rotavirus vaccine, or any other combination thereof, prior to study entry
- Has received a blood transfusion or blood products, including immunoglobulins
- Has participated in another clinical study of an investigational product before the beginning or anytime during the duration of the current clinical study. Participants enrolled in observational studies may be included; these will be reviewed on a case-by-case basis for approval by the Sponsor
- Is or has an immediate family member (eg, parent/legal guardian or sibling) who is investigational site or Sponsor staff directly involved with this study
Exclusion
Key Trial Info
Start Date :
September 4 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 5 2021
Estimated Enrollment :
1184 Patients enrolled
Trial Details
Trial ID
NCT04031846
Start Date
September 4 2019
End Date
August 5 2021
Last Update
July 28 2023
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
Queensland Children s Hospital ( Site 0004)
South Brisbane, Queensland, Australia, 4101
2
Vaccine and Immunisation Research Group - VIRGo ( Site 0002)
Melbourne, Victoria, Australia, 3010
3
Telethon Kids Institute ( Site 0003)
Nedlands, Australia, 6009
4
O.L.V. Ziekenhuis Aalst ( Site 0144)
Aalst, Belgium, 9300